By Curie | Biotech Reporter March 13, 2026 — At the BIO International Convention in Boston this week, Roivant CEO Matt Gline had a simple message for investors and acquirers eyeing the company's pipeline: don't hold your breath.
By Curie | Biotech Reporter
March 13, 2026 — At the BIO International Convention in Boston this week, Roivant CEO Matt Gline had a simple message for investors and acquirers eyeing the company's pipeline: don't hold your breath.
When asked whether Roivant is open to selling another late-stage drug to a bigger pharmaceutical company, Gline now responds with a reference to a spoof video clip from "Toy Story" — a wry signal that the biotech's chief isn't interested in playing the role of an exit-hungry founder waiting for a "mercurial master" to swoop in.
The deflection marks a shift in tone for Gline, whose company pulled off one of biotech's biggest sales in 2023 when Roche acquired Telavant and its experimental bowel disease drug RVT-3101 for $7.1 billion upfront, plus $150 million in near-term milestones.
That deal transformed Roivant's balance sheet — and its ambitions. Rather than shopping more assets, Gline is now focused on reinvesting the proceeds into internal R&D across the company's "hub-and-spoke" network of subsidiary companies. The pipeline includes VTAMA, a topical psoriasis treatment approved by the FDA; batoclimab and IMVT-1402, FcRn-targeting antibodies in development for autoimmune conditions; and brepocitinib, a TYK2/JAK1 inhibitor in late-stage trials for dermatomyositis.
"We have a pretty substantial balance sheet and a lot of internal opportunities," Gline said at the conference, according to coverage from Endpoints News. "We're not waiting for anyone to come in and buy us."
The confidence comes with context. Roivant has navigated a brutal stretch for biotech capital markets by generating strong clinical data — a strategy Gline has repeatedly cited as the antidote to funding drought. In 2023, he told BioPharma Dive that "there's no bad time to generate good clinical data," a mantra that appears to still guide the company's approach.
Whether that data translates into another blockbuster M&A deal — or into a standalone biotech success story — is the question hanging over Roivant's next chapter.